In July 2025, Andersson et al. reported in Annals of Internal Medicine that early-life exposure to Aluminium (Al)-
adjuvanted vaccines was not associated with increased risk of 50 chronic diseases, based on a Danish cohort of
1.2 million children. While widely cited as reassuring evidence of Al-Based Adjuvant (ABA) safety, closer scrutiny
reveals major methodological and conceptual flaws. Specifically, the study demonstrates limited understanding
of Al toxicology, weaknesses in cohort design and statistical analysis, and insufficient transparency regarding
potential conflicts of interest. We argue that these shortcomings prevent meaningful conclusions about ABA
safety, particularly in relation to neurodevelopmental and autoimmune outcomes, and highlight the need for
more rigorous, transparent, and scientifically grounded investigations.
Aluminium adjuvants and childhood health
